To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Prilosec Available In New 40mg Dosage Strength URL: http://www.pslgroup.com/dg/525DA.htm Doctor's Guide January 26, 1998
WAYNE, PA -- January 26, 1998 -- The United States Food and Drug Administration has granted marketing clearance to a 40mg dosage strength of Astra Merck Inc.'s antisecretory prescription medication Prilosec(R) (omeprazole). The 40mg capsule, together with the currently available 10mg and 20mg capsules, provides health care professionals with increased dosing flexibility in the treatment of certain acid-related disorders with the convenience of taking a single 40mg capsule. The 20 mg capsule remains the recommended dosage strength for most indications. The first in a class of antisecretory compounds known as proton pump inhibitors, Prilosec is indicated for use as first-line therapy for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD); with the antibiotic Biaxin(R) (clarithromycin) for the eradication of H. pylori infection associated with duodenal ulcers to reduce the risk of ulcer recurrence; short-term treatment of erosive esophagitis; maintenance of healing of erosive esophagitis; short-term treatment of active duodenal ulcer and active benign gastric ulcer; and treatment of certain pathological hypersecretory conditions. A once-daily 40mg dose of Prilosec is recommended for treatment of gastric ulcer and Helicobacter pylori associated with active duodenal ulcer. For certain pathological hypersecretory conditions such as Zollinger-Ellison syndrome, the starting dose is 60mg once a day. Prilosec is generally well tolerated. Its side effects are usually transient and mild and include headache, diarrhea and abdominal pain. More information on: Prilosec, Astra, Merck --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.